查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950516

溶瘤病毒生產和開發服務市場（按服務類型、規模、病毒類型、合約類型、最終用戶和應用分類），全球預測，2026-2032年

Oncolytic Virus Manufacturing & Development Services Market by Service Type, Scale, Virus Type, Contract Type, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年溶瘤病毒生產和開發服務市值為 3.6033 億美元，預計到 2026 年將成長至 3.7637 億美元，預計到 2032 年將達到 5.5061 億美元，複合年成長率為 6.24%。

關鍵市場統計數據
基準年 2025 3.6033億美元
預計年份：2026年 3.7637億美元
預測年份 2032 5.5061億美元
複合年成長率 (%) 6.24%

為相關人員提供簡明扼要、全面整合的介紹，闡述影響腫瘤病毒生產和開發過程的科學、營運和監管要求。

溶瘤病毒作為治療方法的出現，徹底改變了癌症的研究和開發，同時也對科學、生產和監管領域提出了更高的要求。如今，溶瘤病毒療法的研發人員面臨著細胞生物學、載體工程和臨床應用之間錯綜複雜的交叉領域，需要協調上游工程和下游製程。隨著治療方法從實驗室走向臨床試驗，生產安全、高效且可重複的病毒製劑的技術和操作複雜性顯著增加，因此嚴格的製程控制、可靠的分析框架和可擴展的生產策略至關重要。

技術創新、聯合治療策略以及不斷變化的監管要求如何重塑溶瘤病毒研發和生產中的決策

近年來，技術進步、不斷更新的臨床證據和市場動態重塑了研發策略，為溶瘤病毒領域帶來了變革性變化。載體設計的創新，包括提高腫瘤選擇性和引入免疫調節有效載荷，正在擴大治療範圍並推動生產流程的改進。同時，用於鑑定、效力測定和雜質分析的分析方法的進步，使得更科學的工藝最佳化和可比性評估成為可能。

評估2025年實施的關稅變化對溶瘤病毒研發和生產網路在供應鏈、採購和營運方面的累積影響

美國自2025年起實施的關稅政策不斷升級，為支持溶瘤病毒生產的國際供應鏈帶來了新的挑戰。採購專用原料、一次性組件和特定設備的成本上升和挑戰日益加劇，迫使各企業重新評估供應商結構和物流模式。為此，許多研發商和服務供應商正加緊努力，實現供應商多元化，合格替代材料，並重新談判合約條款，以在確保供應連續性的同時控制不斷上漲的成本。

將服務類型、病毒式傳播平台、最終用戶、用例、合約模式和規模需求與開發優先順序相匹配的實用細分洞察

精細化的市場區隔框架識別出溶瘤病毒市場中技術需求、採購選擇和合作夥伴模式的差異領域。就服務類型而言，需求涵蓋分析服務、細胞株開發、填充、生產、製程開發、純化、品管和法規支援等各個面向。生產本身又根據臨床、商業和臨床前階段進行區分，其中臨床生產進一步細分為I/II期和III期需求。每種服務類型都有不同的性能指標要求：分析服務需要提供高靈敏度和特異性的檢測方法；細胞株開發需要穩定性和可擴展性；填充表面處理工程則需要在保持無菌性和產量以及配方兼容性之間取得平衡。

美洲、歐洲、中東和非洲以及亞太地區的區域製造能力、監管多樣性和生態系統成熟度將如何影響戰略採購和發展路徑

區域洞察揭示了產能、監管細則和商業性動態如何影響製造商和申辦者的採購和夥伴關係決策。在美洲，成熟的合約研發生產機構 (CDMO) 生態系統，以及生物技術創新者和大型製藥申辦者的高度位置，共同促進了快速的臨床轉化和強大的研發供應商合作。該地區的監管機構繼續優先考慮核准後生產變更的可比性和清晰度，因此，與負責人的早期溝通和詳盡的分析報告對於獲得核准至關重要。

主要企業的能力和夥伴關係模式決定了其在溶瘤病毒製程開發、生產和監管支援方面的競爭優勢

憑藉在細胞株設計、製程改進和分析創新方面的差異化能力，主要企業和專業服務供應商正日益塑造裂解病毒開發領域的營運格局。無論是新參與企業還是成熟的契約製造，都在投資於平台技術，以加速規模化生產，同時降低成本並維持產品品質。這些投資包括先進的一次性技術、封閉式處理系統和自動化分析技術，這些技術能夠減少人工干預並提高可重複性。

為製造商、開發商和策略合作夥伴提供切實可行的、影響深遠的建議，以提高溶瘤療法計畫的韌性、監管準備和可擴展生產能力。

產業領導者應優先考慮一系列切實可行的舉措，以提高裂解病毒領域的專案可預測性和商業化準備度。首先，在研發生命週期的早期階段，將分析方法開發與效力研究設計相結合，以建立能夠經受監管審查的穩健的可比性和批次放行標準。將分析方法開發與上游工程和下游製程最佳化並行開展，可以減少後期階段出現意外問題，並縮短關鍵研究週期。

一套穩健透明的調查方法，結合了關鍵相關人員訪談、監管審查和技術流程分析，為營運和策略決策提供支援。

本研究採用多維度調查方法，結合了對高級技術和商業相關人員者的訪談、對監管指導文件的嚴格審查以及對製造和服務供應商能力的詳細分析。主要定性訪談收集了製程開發科學家、品質保證和法規事務人員、供應鏈經理以及商業負責人的觀點，以確保對整個開發生命週期有全面的了解。此外，還對同行評審文獻、已發布的監管指導文件、技術白皮書和供應商規範進行了二次分析，檢驗技術聲明並將其與行業最佳實踐相結合。

對決定溶瘤病毒開發專案成敗的營運、供應鏈和策略要務進行全面分析

分析表明，溶瘤病毒的研發正處於轉折點。科學進步與操作技術的成熟融合，為改善患者療效和商業性成功創造了實際機會。從早期概念到臨床概念驗證，最終實現商業化，關鍵在於細胞株設計、製程開發和分析方法的嚴謹整合。那些能夠及早利用跨職能專業知識、優先開發檢測方法並設計可擴展製程的機構，將能夠降低技術風險並加速研發進程。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 溶瘤病毒生產和開發服務市場（按服務類型分類）

  • 分析服務
  • 細胞株構建
  • 灌裝/包裝
  • 製造業
    • 臨床生產
    • 商業生產
    • 臨床前生產
  • 製程開發
  • 純化
  • 品管
  • 監管支持

第9章 溶瘤病毒生產與開發服務市場規模

  • 臨床階段
    • 第一階段/第二階段
    • 第三階段
  • 商業的
  • 臨床前

10. 溶瘤病毒生產和開發服務市場（按病毒類型分類）

  • 腺病毒
  • 單純皰疹病毒
  • 麻疹病毒
  • 新城疫病毒
  • 呼腸孤病毒
  • 牛痘病毒

第11章 溶瘤病毒生產與開發服務市場（依合約類型分類）

  • 聯合調查
  • 服務型合約
  • 合資企業
  • 授權合約

12. 依最終用戶分類的溶瘤病毒生產與開發服務市場

  • 學術研究機構
  • 生技公司
  • CRO（受託研究機構）
  • 醫院
  • 製藥公司

第13章 溶瘤病毒生產與開發服務市場（依應用領域分類）

  • 骨髓惡性腫瘤
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固態腫瘤
    • 乳癌
    • 大腸直腸癌
    • 肺癌
    • 黑色素瘤

14. 各區域溶瘤病毒生產及開發服務市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 溶瘤病毒生產與開發服務市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國溶瘤病毒生產及開發服務市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國溶瘤病毒生產與開發服務市場

第18章：中國溶瘤病毒生產與開發服務市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ABL, Inc.
  • AGC Biologics, Inc.
  • Amgen Inc.
  • Catalent, Inc.
  • Creative Biogene Co., Ltd.
  • Danaher Corporation
  • Elise Biopharma GmbH
  • Fujifilm Diosynth Biotechnologies
  • IDT Biologika GmbH
  • Lonza Group AG
  • Merck KGaA
  • Oncolys BioPharma, Inc.
  • Oncolytics Biotech Inc.
  • Oxford Biomedica plc
  • PsiOxus Therapeutics Ltd.
  • Recipharm AB
  • Replimune Group, Inc.
  • Sartorius AG
  • SillaJen, Inc.
  • Theriva Biologics, Inc.
  • Thermo Fisher Scientific Inc.
  • TILT Biotherapeutics Oy
  • Transgene SA
  • Viralytics Ltd.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-4F7A6D4FD8B3

The Oncolytic Virus Manufacturing & Development Services Market was valued at USD 360.33 million in 2025 and is projected to grow to USD 376.37 million in 2026, with a CAGR of 6.24%, reaching USD 550.61 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 360.33 million
Estimated Year [2026] USD 376.37 million
Forecast Year [2032] USD 550.61 million
CAGR (%) 6.24%

A concise, integrated introduction to the scientific, operational, and regulatory imperatives shaping oncolytic virus manufacturing and development pathways for stakeholders

The emergence of oncolytic viruses as a therapeutic modality has transformed cancer research and development, creating parallel demands across scientific, manufacturing, and regulatory domains. Developers pursuing oncolytic approaches now confront a dense intersection of cell biology, vector engineering, and clinical translation that requires harmonized upstream and downstream processes. As therapies move from bench toward clinical testing, the technical and operational complexity of producing safe, potent, and reproducible viral products increases substantially, demanding rigorous process controls, robust analytical frameworks, and scalable manufacturing strategies.

This introduction frames the critical levers for program success: selection and optimization of viral platforms, establishment of stable cell substrates and cell line development practices, development of validated purification and fill-finish processes, and alignment with evolving regulatory expectations for potency, purity, and safety. Moreover, the industry context is shaped by shifting commercial priorities, where sponsors must balance accelerated timelines with quality by design and risk-based approaches. In the current landscape, sponsors who integrate cross-functional expertise early can reduce downstream delays and ensure smoother transitions between preclinical, clinical, and commercial phases.

Transitioning from conceptual designs to operational plans requires disciplined technical transfer, strategic partner selection, and a clear understanding of contract structures that affect control, costs, and timelines. This document establishes that foundation by identifying core manufacturing and development considerations, mapping the primary areas where investment yields disproportionate returns, and clarifying how organizational choices influence the ability to deliver on clinical and commercial objectives.

How technological innovations, combination therapy strategies, and evolving regulatory expectations are reshaping oncolytic virus development and manufacturing decision making

Recent years have seen transformative shifts in the oncolytic virus landscape driven by technological advances, evolving clinical evidence, and market dynamics that reframe development strategies. Innovations in vector design, including improved tumor selectivity and immune-modulatory payloads, are expanding the therapeutic scope and prompting refinements to manufacturing workflows. Concurrently, improvements in analytical methods for identity, potency, and impurity profiling are enabling more informed process optimization and comparability assessments.

Clinical strategies have diversified as combination approaches with immune checkpoint inhibitors and other immunotherapies demonstrate additive or synergistic effects, encouraging sponsors to design manufacturing strategies that can support combination regimens and varied dosing paradigms. These scientific shifts are complemented by a maturing ecosystem of contract developers and manufacturers that offer modularized services across cell line development, process development, and commercial-scale production. As a consequence, sponsors now have more pathways to de-risk development through strategic outsourcing and alliance models that preserve agility while accessing specialized capabilities.

Regulatory expectations have also progressed, emphasizing lifecycle control, robust characterization, and post-approval manufacturing oversight. As a result, organizations are adopting quality-by-design principles and investing earlier in analytical development and control strategies to meet dossier expectations. Taken together, these trends create both opportunities and responsibilities for developers: adopt new capabilities rapidly while embedding rigorous process and quality systems to ensure reproducible clinical performance and patient safety.

Assessing the cumulative supply chain, procurement, and operational consequences of tariff changes introduced in 2025 on oncolytic virus development and manufacturing networks

The introduction and escalation of United States tariffs in 2025 have imposed new considerations across international supply chains that support oncolytic virus manufacturing. Procurement of specialized raw materials, single-use components, and certain instrumentation has encountered additional cost pressures and sourcing complexities, prompting organizations to reassess supplier footprints and logistics models. In response, many developers and service providers have intensified efforts to diversify suppliers, qualify alternate materials, and renegotiate terms to preserve continuity of supply while managing cost inflation.

These tariff-driven dynamics have also influenced nearshoring and reshoring dialogues, with some sponsors evaluating regional manufacturing strategies to reduce exposure to cross-border trade risks. Such shifts increase the value of local manufacturing capacity but may also require capital investments in facilities, workforce training, and regulatory harmonization efforts. Simultaneously, contract manufacturers are recalibrating procurement strategies and inventory policies to buffer clients from supply interruptions, which in turn affects lead times and working capital requirements.

Importantly, the cumulative impact of tariff changes has accelerated adoption of strategic risk management practices across sponsor portfolios. Portfolio prioritization, component standardization, and early supplier engagement now occupy more prominent roles in program planning. As stakeholders adapt, they are increasingly focused on building resilient supply chains that combine diversified sourcing, regional manufacturing options, and contractual protections to mitigate price volatility and sustain uninterrupted development timelines.

Actionable segmentation-based insights that align service types, viral platforms, end users, applications, contract models, and scale requirements to development priorities

A nuanced segmentation framework clarifies where technical needs, procurement choices, and partner models diverge across the oncolytic virus market. When considering service type, demands range from analytical services and cell line development to fill and finish, manufacturing, process development, purification, quality control, and regulatory support, with manufacturing itself differentiating by clinical, commercial, and preclinical stages and clinical manufacturing subdivided into Phase I/II and Phase III needs. Each service type imposes different performance metrics: analytical work must deliver sensitive and specific assays, cell line development must ensure stability and scalability, and fill-finish operations must balance aseptic integrity with throughput and formulation compatibility.

Scale-based segmentation further refines operational requirements as clinical, commercial, and preclinical programs exhibit distinct throughput, quality control depth, and process robustness expectations; within clinical scale, Phase I/II demands rapid iterative flexibility while Phase III requires greater process consistency and validation readiness. Virus type segmentation illustrates modality-specific manufacturing considerations: adenovirus constructs often require distinct upstream cell systems and purification strategies compared with herpes simplex virus, measles virus, Newcastle disease virus, reovirus, or vaccinia virus platforms, each presenting unique stability, host-cell impurity, and potency assay challenges.

End-user segmentation captures differing objectives and operational sophistication across academic research institutes, biotech companies, contract research organizations, hospitals, and pharmaceutical companies; academic groups may prioritize proof-of-concept flexibility while commercial sponsors emphasize regulatory compliance and supply chain robustness. Application segmentation highlights therapeutic focus areas in hematological malignancies versus solid tumors, with hematological indications such as leukemia, lymphoma, and multiple myeloma requiring specialized dosing and distribution considerations, and solid tumor indications like breast, colorectal, lung cancers, and melanoma demanding targeted delivery strategies and tumor microenvironment considerations. Contract type segmentation delineates how collaborative research, fee-for-service, joint ventures, and license agreements distribute technical responsibilities, risk, and IP control, thereby influencing partner selection, timeline expectations, and the scope of technology transfer activities. Together, this segmented view enables sponsors and service providers to align capabilities to program stage, modality, and strategic intent to optimize resource allocation and development trajectories.

How regional manufacturing capacity, regulatory diversity, and ecosystem maturity across the Americas, EMEA, and Asia-Pacific influence strategic sourcing and development pathways

Regional insights reveal where capacity, regulatory nuance, and commercial dynamics shape sourcing and partnership decisions for manufacturers and sponsors alike. In the Americas, a well-developed ecosystem of contract development and manufacturing organizations, coupled with a dense concentration of biotech innovators and large pharmaceutical sponsors, supports rapid clinical translation and strong developer-vendor collaboration. Regulatory agencies in the region continue to emphasize clarity around comparability and post-approval manufacturing changes, necessitating early engagement with reviewers and thorough analytical packages to support approvals.

Europe, Middle East & Africa present a heterogeneous landscape where centers of excellence coexist with emerging research hubs, and where regulatory frameworks across jurisdictions require harmonized clinical and manufacturing strategies that account for cross-border differences. Sponsors operating in this region benefit from engaging local regulatory expertise and leveraging established manufacturing clusters for clinical and commercial supply, while also anticipating variable reimbursement and health-system access considerations that can influence go-to-market sequencing.

Asia-Pacific is characterized by rapid expansion of manufacturing capacity, increasing local technical expertise, and a growing pipeline of biologics and advanced therapies. Governments and regional stakeholders are investing in biotechnology infrastructure, which expands options for clinical and commercial manufacturing but also requires careful navigation of local regulatory pathways and quality expectations. Across all regions, sponsors must weigh advantages of localized capacity against the need for global comparability, ensuring that process controls and analytical methods support multi-region registration strategies and long-term supply resilience.

Key company-level capabilities and partnership models that determine competitive advantage in oncolytic virus process development, manufacturing, and regulatory support

Leading companies and specialized service providers increasingly define the operational contours of the oncolytic virus development landscape through differentiated capabilities in cell line engineering, process intensification, and analytical innovation. Market entrants and established contract manufacturers alike are investing in platform technologies that accelerate scale-up while reducing costs and preserving product quality. These investments include advanced single-use technologies, closed processing systems, and automated analytics that reduce manual intervention and improve reproducibility.

Strategic partnerships between developers and manufacturers are becoming more structured and longer term, reflecting the need to manage complex transfers and scale transitions. Companies that offer integrated service suites-from early-stage cell line development through clinical manufacturing and regulatory support-tend to attract programs that value continuity and reduced technology transfer risk. At the same time, nimble niche providers specializing in a particular virus platform or analytical domain can offer differentiated value for sponsors with specialized technical needs.

Competitive differentiation increasingly centers on proven regulatory track records, demonstrated capacity to support multi-phase programs, and the ability to adapt processes for combination therapies and novel formulations. Companies that combine technical depth with robust quality systems and transparent communication practices position themselves as preferred partners for both emerging biotech sponsors and established pharmaceutical firms seeking reliable operational partners.

Practical, high-impact recommendations for manufacturers, developers, and strategic partners to improve program resilience, regulatory readiness, and scalable production of oncolytic therapies

Industry leaders should prioritize a set of pragmatic actions to strengthen program predictability and commercial readiness in the oncolytic virus space. First, integrate analytical development and potency assay design early in the development lifecycle to enable robust comparability and batch-release criteria that will withstand regulatory scrutiny. Embedding analytical development alongside upstream and downstream optimization reduces late-stage surprises and shortens timelines for pivotal studies.

Second, adopt flexible manufacturing architectures that allow seamless transitions between preclinical, clinical, and commercial scales; this includes investing in platform process elements that can be scaled with minimal re-validation, using single-use systems where appropriate, and developing clear technology transfer documentation to mitigate risks during partner handoffs. Third, actively manage supply chain resilience by qualifying multiple suppliers for critical raw materials, evaluating regional manufacturing options, and including contractual protections that address tariff and trade volatility. These actions reduce program susceptibility to disruption and provide greater control over lead times and costs.

Finally, cultivate collaborative contracting models that balance sponsor oversight with manufacturer expertise, whether through fee-for-service agreements, joint ventures, or licensing arrangements. These models should align incentives around timelines, quality metrics, and intellectual property management to foster long-term partnerships that support successful commercialization. Taken together, these recommendations provide an actionable roadmap for leaders seeking to translate scientific promise into sustainable therapeutic programs.

A robust, transparent research methodology combining primary stakeholder interviews, regulatory review, and technical process analysis to support operational and strategic decision making

This research applied a multi-dimensional methodology that combined primary interviews with senior technical and commercial stakeholders, rigorous review of regulatory guidance documents, and detailed mapping of manufacturing and service provider capabilities. Primary qualitative interviews captured perspectives from process development scientists, quality assurance and regulatory affairs leads, supply chain managers, and commercial officers to ensure a holistic view across the development lifecycle. These insights were complemented by secondary analysis of peer-reviewed literature, published regulatory guidance, technical white papers, and vendor specifications to validate technical assertions and contextualize industry best practices.

Technical assessments focused on core process elements: cell line development practices, upstream and downstream processing choices, purification and formulation considerations, fill-finish constraints, and analytical method development. Case-based comparisons illustrated how different virus platforms influence process steps and regulatory expectations. Supply chain and procurement analyses evaluated the implications of tariff changes, material lead times, and regional manufacturing capacity. Throughout the analysis, findings were corroborated through triangulation of sources, cross-validated with domain experts, and synthesized into actionable recommendations that reflect both technical feasibility and commercial realities.

Methodological limitations were addressed by transparently documenting assumptions, noting areas where proprietary data were not available, and identifying topics where ongoing surveillance of regulatory updates and technological advances is required. The result is a pragmatic, evidence-based study designed to inform near-term operational decisions and longer-term strategic planning for stakeholders engaged in oncolytic virus development.

Concluding synthesis on the operational, supply chain, and strategic imperatives that collectively determine the success of oncolytic virus development programs

This analysis concludes that oncolytic virus development sits at an inflection point where scientific advances and operational sophistication converge to create tangible opportunities for improved patient outcomes and commercial success. The pathway from early-stage concept to clinical proof-of-concept and eventual commercialization depends on disciplined integration of cell line engineering, process development, and analytical rigor. Organizations that engage cross-functional expertise early, prioritize assay development, and design scalable processes stand to reduce technical risk and accelerate timelines.

Supply chain dynamics, including the impacts of recent tariff changes, have introduced an additional layer of complexity that requires sponsors to proactively manage supplier networks and consider regional manufacturing strategies where appropriate. Strategic contracting and partnership models that allocate responsibilities and align incentives can mitigate execution risks and preserve program momentum. Moreover, modality-specific considerations-such as the differing upstream and purification needs of adenovirus versus herpes simplex or vaccinia platforms-demand tailored manufacturing solutions rather than one-size-fits-all approaches.

In sum, the successful development of oncolytic virus therapies will be driven by a combination of technical excellence, supply chain resilience, and strategic partnerships that together enable reliable production, regulatory compliance, and effective clinical execution. Stakeholders who adopt these principles will be better positioned to translate scientific promise into sustained therapeutic impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oncolytic Virus Manufacturing & Development Services Market, by Service Type

  • 8.1. Analytical Services
  • 8.2. Cell Line Development
  • 8.3. Fill & Finish
  • 8.4. Manufacturing
    • 8.4.1. Clinical Manufacturing
    • 8.4.2. Commercial Manufacturing
    • 8.4.3. Preclinical Manufacturing
  • 8.5. Process Development
  • 8.6. Purification
  • 8.7. Quality Control
  • 8.8. Regulatory Support

9. Oncolytic Virus Manufacturing & Development Services Market, by Scale

  • 9.1. Clinical
    • 9.1.1. Phase I/II
    • 9.1.2. Phase III
  • 9.2. Commercial
  • 9.3. Preclinical

10. Oncolytic Virus Manufacturing & Development Services Market, by Virus Type

  • 10.1. Adenovirus
  • 10.2. Herpes Simplex Virus
  • 10.3. Measles Virus
  • 10.4. Newcastle Disease Virus
  • 10.5. Reovirus
  • 10.6. Vaccinia Virus

11. Oncolytic Virus Manufacturing & Development Services Market, by Contract Type

  • 11.1. Collaborative Research
  • 11.2. Fee-for-Service
  • 11.3. Joint Ventures
  • 11.4. License Agreements

12. Oncolytic Virus Manufacturing & Development Services Market, by End User

  • 12.1. Academic Research Institutes
  • 12.2. Biotech Companies
  • 12.3. Contract Research Organizations
  • 12.4. Hospitals
  • 12.5. Pharmaceutical Companies

13. Oncolytic Virus Manufacturing & Development Services Market, by Application

  • 13.1. Hematological Malignancies
    • 13.1.1. Leukemia
    • 13.1.2. Lymphoma
    • 13.1.3. Multiple Myeloma
  • 13.2. Solid Tumors
    • 13.2.1. Breast Cancer
    • 13.2.2. Colorectal Cancer
    • 13.2.3. Lung Cancer
    • 13.2.4. Melanoma

14. Oncolytic Virus Manufacturing & Development Services Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Oncolytic Virus Manufacturing & Development Services Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Oncolytic Virus Manufacturing & Development Services Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Oncolytic Virus Manufacturing & Development Services Market

18. China Oncolytic Virus Manufacturing & Development Services Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. ABL, Inc.
  • 19.6. AGC Biologics, Inc.
  • 19.7. Amgen Inc.
  • 19.8. Catalent, Inc.
  • 19.9. Creative Biogene Co., Ltd.
  • 19.10. Danaher Corporation
  • 19.11. Elise Biopharma GmbH
  • 19.12. Fujifilm Diosynth Biotechnologies
  • 19.13. IDT Biologika GmbH
  • 19.14. Lonza Group AG
  • 19.15. Merck KGaA
  • 19.16. Oncolys BioPharma, Inc.
  • 19.17. Oncolytics Biotech Inc.
  • 19.18. Oxford Biomedica plc
  • 19.19. PsiOxus Therapeutics Ltd.
  • 19.20. Recipharm AB
  • 19.21. Replimune Group, Inc.
  • 19.22. Sartorius AG
  • 19.23. SillaJen, Inc.
  • 19.24. Theriva Biologics, Inc.
  • 19.25. Thermo Fisher Scientific Inc.
  • 19.26. TILT Biotherapeutics Oy
  • 19.27. Transgene S.A.
  • 19.28. Viralytics Ltd.
  • 19.29. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ANALYTICAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ANALYTICAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ANALYTICAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CELL LINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CELL LINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY FILL & FINISH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY FILL & FINISH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY FILL & FINISH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PROCESS DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PURIFICATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PURIFICATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY QUALITY CONTROL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY QUALITY CONTROL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY QUALITY CONTROL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY SUPPORT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY SUPPORT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REGULATORY SUPPORT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHASE I/II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHASE I/II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHASE I/II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ADENOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ADENOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HERPES SIMPLEX VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MEASLES VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MEASLES VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MEASLES VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY NEWCASTLE DISEASE VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VACCINIA VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VACCINIA VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VACCINIA VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COLLABORATIVE RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COLLABORATIVE RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COLLABORATIVE RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY FEE-FOR-SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY FEE-FOR-SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY FEE-FOR-SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY JOINT VENTURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY JOINT VENTURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY JOINT VENTURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LICENSE AGREEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LICENSE AGREEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LICENSE AGREEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 233. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 234. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY MANUFACTURING, 2018-2032 (USD MILLION)
  • TABLE 236. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SCALE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CLINICAL, 2018-2032 (USD MILLION)
  • TABLE 238. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY VIRUS TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY CONTRACT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, 2018-2032 (USD MILLION)
  • TABLE 243. GCC ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION ONCOLYTIC VIRUS MANUFACTURING & DEVELOPMENT SERVICES MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION ONCOLYTIC VIRUS MANUFACTURING &